nach oben

Pediatric Drugs

Erschienen in:

01.08.2018 | Review article

Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter

verfasst von: Praveen Kumar Conjeevaram Selvakumar, Mohammad Nasser Kabbany, Naim Alkhouri

Erschienen in: Pediatric Drugs | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased substantially in the past two decades and NAFLD has now become the most common cause of chronic liver disease in children and adolescents. NAFLD is a broad clinicopathologic spectrum ranging from simple steatosis to varying degrees of necroinflammation called nonalcoholic steatohepatitis (NASH), leading to fibrosis and subsequently to cirrhosis. Despite the increasing prevalence and progressive nature of NAFLD even among children, therapy for NAFLD in both adults and children are limited. Weight loss remains the only consistently effective therapy for NAFLD. Pharmacologic options are even more limited in children than in adults with NAFLD. Vitamin E has been shown to be effective in improving histology in children with NASH. Few pharmacologic options such as metformin, probiotics, omega-3 fatty acids, and cysteamine bitartrate have been studied in children, with limited beneficial effects. However, these studies are limited by small sample size and heterogeneity of outcome assessment after treatment. Recent studies show promising results with bariatric surgery with regards to weight loss and improvement in liver histology in adolescents with NAFLD. In this review article, we discuss epidemiology, pathophysiology, and extrahepatic comorbidities of pediatric NAFLD and review existing therapeutic options for children with NAFLD. We also review novel therapeutic strategies studied in adults that could potentially be studied in children in the future.

Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983;78:374–7.PubMed

Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism. 2016;65:1080–6. https://doi.org/10.1016/j.metabol.2015.11.008.PubMedCrossRef

Kleiner DE, Makhlouf HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis. 2016;20:293–312. https://doi.org/10.1016/j.cld.2015.10.011.PubMedCrossRef

Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538–44. https://doi.org/10.1136/gut.2008.171280.PubMedPubMedCentralCrossRef

Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388–93. https://doi.org/10.1542/peds.2006-1212.PubMedCrossRef

Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50:1282–93. https://doi.org/10.1002/hep.23119.PubMedPubMedCentralCrossRef

Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US Children, 1999-2016. Pediatrics. 2018;141:e20173459. https://doi.org/10.1542/peds.2017-3459.CrossRef

Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology. 2007;133:1814–20. https://doi.org/10.1053/j.gastro.2007.08.077.PubMedPubMedCentralCrossRef

Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr. 2013;162(496–500):e1. https://doi.org/10.1016/j.jpeds.2012.08.043.CrossRef

10.

Lawlor DA, Callaway M, Macdonald-Wallis C, Anderson E, Fraser A, Howe LD, et al. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents. J Clin Endocrinol Metab. 2014;99:E410–7. https://doi.org/10.1210/jc.2013-3612.PubMedPubMedCentralCrossRef

11.

Anderson EL, Howe LD, Jones HE, Higgins JPT, Lawlor DA, Fraser A, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015;10:e0140908. https://doi.org/10.1371/journal.pone.0140908.PubMedPubMedCentralCrossRef

12.

Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. 2016. https://doi.org/10.1053/j.gastro.2016.03.009.

13.

Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 2005;115(5):e561–5.PubMedCrossRef

14.

Angulo P. Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? Hepatology. 2010;51:373–5. https://doi.org/10.1002/hep.23521.PubMedPubMedCentralCrossRef

15.

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(389–97):e10. https://doi.org/10.1053/j.gastro.2015.04.043.CrossRef

16.

Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–54. https://doi.org/10.1002/hep.27368.PubMedCrossRef

17.

Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234–8. https://doi.org/10.1016/j.cgh.2008.11.005.PubMedCrossRef

18.

Alkhouri N, Sedki E, Alisi A, Lopez R, Pinzani M, Feldstein AE, et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int. 2013;33:79–85. https://doi.org/10.1111/liv.12024.PubMedCrossRef

19.

Carter-Kent C, Brunt EM, Yerian LM, Alkhouri N, Angulo P, Kohli R, et al. Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2011;52:190–7. https://doi.org/10.1097/MPG.0b013e3181fb47d3.PubMedCrossRef

20.

Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, et al. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci. 2015;60:1440–7. https://doi.org/10.1007/s10620-014-3494-7.PubMedCrossRef

21.

Eng K, Lopez R, Liccardo D, Nobili V, Alkhouri N. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. Dig Liver Dis. 2014. https://doi.org/10.1016/j.dld.2014.07.016.PubMedCrossRef

22.

Alkhouri N, Mansoor S, Giammaria P, Liccardo D, Lopez R, Nobili V. The development of the Pediatric NAFLD Fibrosis Score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. PLoS One 2014; 9. https://doi.org/10.1371/journal.pone.0104558.

23.

Kabbany MN, Selvakumar PKC, Watt K, Lopez R, Akras Z, Zein N, et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the united states: an analysis of national health and nutrition examination survey data. Am J Gastroenterol. 2017;112:581–7. https://doi.org/10.1038/ajg.2017.5.PubMedCrossRef

24.

Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the united states. Gastroenterology. 2015;148:547–55. https://doi.org/10.1053/j.gastro.2014.11.039.PubMedCrossRef

25.

Alkhouri N, Hanouneh IA, Zein NN, Lopez R, Kelly D, Eghtesad B, et al. Liver transplantation for nonalcoholic steatohepatitis in young patients. Transpl Int. 2016;29:418–24. https://doi.org/10.1111/tri.12694.PubMedCrossRef

26.

Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174–97. https://doi.org/10.1002/hep.26717.PubMedCrossRef

27.

Selvakumar PKC, Kabbany MN, Nobili V, Alkhouri N. Nonalcoholic fatty liver disease in children. Pediatr Clin North Am. 2017;64:659–75. https://doi.org/10.1016/j.pcl.2017.01.008.PubMedCrossRef

28.

Alkhouri N, Selvakumar PKC, Kabbany MN, Lopez R, Mosca A, Della Corte C, et al. Extrahepatic complications are extremely common in children with nonalcoholic fatty liver disease (NAFLD) and their frequency correlates with NAFLD histologic severity. Gastroenterology. 2016;150:S1172. https://doi.org/10.1016/S0016-5085(16)33961-0.CrossRef

29.

Koskinen J, Magnussen CG, Kähönen M, Loo B-M, Marniemi J, Jula A, et al. Association of liver enzymes with metabolic syndrome and carotid atherosclerosis in young adults. The Cardiovascular Risk in Young Finns Study. Ann Med. 2012;44:187–95. https://doi.org/10.3109/07853890.2010.532152.PubMedCrossRef

30.

Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–8. https://doi.org/10.2337/dc06-2247.PubMedCrossRef

31.

Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277–83. https://doi.org/10.1161/CIRCULATIONAHA.107.739920.PubMedPubMedCentralCrossRef

32.

Nobili V, Alkhouri N, Bartuli A, Manco M, Lopez R, Alisi A, et al. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res. 2010;67:665–70. https://doi.org/10.1203/PDR.0b013e3181da4798.PubMedCrossRef

33.

Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, et al. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015;60:360–7. https://doi.org/10.1097/MPG.0000000000000584.PubMedPubMedCentralCrossRef

34.

Schwimmer JB, Zepeda A, Newton KP, Xanthakos SA, Behling C, Hallinan EK, et al. Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS ONE. 2014;9:e112569. https://doi.org/10.1371/journal.pone.0112569.PubMedPubMedCentralCrossRef

35.

Sert A, Pirgon O, Aypar E, Yilmaz H, Odabas D. Relationship between left ventricular mass and carotid intima media thickness in obese adolescents with non-alcoholic fatty liver disease. J Pediatr Endocrinol Metab. 2012;25:927–34. https://doi.org/10.1515/jpem-2012-0187.PubMedCrossRef

36.

Pacifico L, Di Martino M, De Merulis A, Bezzi M, Osborn JF, Catalano C, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology. 2014;59:461–70. https://doi.org/10.1002/hep.26610.PubMedCrossRef

37.

Fintini D, Chinali M, Cafiero G, Esposito C, Giordano U, Turchetta A, et al. Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutr Metab Cardiovasc Dis. 2014;24:72–4. https://doi.org/10.1016/j.numecd.2013.06.005.PubMedCrossRef

38.

39.

Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the edinburgh type 2 diabetes study. Diabetes Care. 2011;34:1139–44. https://doi.org/10.2337/dc10-2229.PubMedPubMedCentralCrossRef

40.

Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology. 2009;50:1113–20. https://doi.org/10.1002/hep.23133.PubMedPubMedCentralCrossRef

41.

Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143:500–5. https://doi.org/10.1067/S0022-3476(03)00325-1.PubMedCrossRef

42.

Newton KP, Hou J, Crimmins NA, Lavine JE, Barlow SE, Xanthakos SA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr 2016; p. e161971. https://doi.org/10.1001/jamapediatrics.2016.1971.

43.

Narang I, Mathew JL. Childhood obesity and obstructive sleep apnea. J Nutr Metab. 2012;2012:134202. https://doi.org/10.1155/2012/134202.PubMedPubMedCentralCrossRef

44.

Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest. 2010;137:711–9. https://doi.org/10.1378/chest.09-0360.PubMedPubMedCentralCrossRef

45.

Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev. 2013;14:417–31. https://doi.org/10.1111/obr.12020.PubMedCrossRef

46.

Sundaram SS, Sokol RJ, Capocelli KE, Pan Z, Sullivan JS, Robbins K, et al. Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease. J Pediatr. 2014;164(699–706):e1. https://doi.org/10.1016/j.jpeds.2013.10.072.CrossRef

47.

Nobili V, Cutrera R, Liccardo D, Pavone M, Devito R, Giorgio V, et al. Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med. 2014;189:66–76. https://doi.org/10.1164/rccm.201307-1339OC.PubMedCrossRef

48.

Pacifico L, Bezzi M, Lombardo CV, Romaggioli S, Ferraro F, Bascetta S, et al. Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease. World J Gastroenterol. 2013;19:4007–14. https://doi.org/10.3748/wjg.v19.i25.4007.PubMedPubMedCentralCrossRef

49.

Pardee PE, Dunn W, Schwimmer JB. Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment Pharmacol Ther. 2012;35:248–54. https://doi.org/10.1111/j.1365-2036.2011.04924.x.PubMedCrossRef

50.

Pirgon O, Bilgin H, Tolu I, Odabas D. Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2011;75:189–95. https://doi.org/10.1111/j.1365-2265.2011.04038.x.CrossRef

51.

Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836–46. https://doi.org/10.1002/hep.24001.PubMedCrossRef

52.

Musso G, Paschetta E, Gambino R, Cassader M, Molinaro F. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med. 2013;19:522–35. https://doi.org/10.1016/j.molmed.2013.05.006.PubMedCrossRef

53.

Koot BGP, Van Der Baan-Slootweg OH, Bohte AE, Nederveen AJ, Van Werven JR, Tamminga-Smeulders CLJ, et al. Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity. 2013;21:583–90. https://doi.org/10.1002/oby.20173.PubMedCrossRef

54.

Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dhawan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatr Obes. 2012;7:471–9. https://doi.org/10.1111/j.2047-6310.2012.00082.x.PubMedCrossRef

55.

Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobolczyk J, Kaczmarski M. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. Adv Med Sci. 2009;54:177–82. https://doi.org/10.2478/v10039-009-0047-y.PubMedCrossRef

56.

Poeta M, Pierri L, Vajro P. Gut-liver axis derangement in non-alcoholic fatty liver disease. Children. 2017;4:66. https://doi.org/10.3390/children4080066.PubMedCentralCrossRef

57.

Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10:637–44. https://doi.org/10.1038/nrgastro.2013.146.PubMedCrossRef

58.

Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:7381–91. https://doi.org/10.3748/wjg.v20.i23.7381.PubMedPubMedCentralCrossRef

59.

Nakamoto N, Kanai T. Role of Toll-like receptors in immune activation and tolerance in the liver. Front Immunol. 2014;5:1–8. https://doi.org/10.3389/fimmu.2014.00221.CrossRef

60.

Krawczyk M, Rau M, Schattenberg JM, Bantel H, Pathil A, Demir M, et al. Combined effects of the TM6SF2 rs58542926, PNPLA3 rs738409 and MBOAT7 rs641738 variants on NAFLD severity: multicentre biopsy-based study. J Lipid Res 2016; 58. https://doi.org/10.1194/jlr.p067454.

61.

Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy T, et al. Chronic overexpression of PNPLA3I148 M in mouse liver causes hepatic steatosis. J Clin Invest. 2012;122:4130–44. https://doi.org/10.1172/JCI65179.PubMedPubMedCentralCrossRef

62.

Goffredo M, Caprio S, Feldstein AE, D’Adamo E, Shaw MM, Pierpont B, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: a multiethnic study. Hepatology. 2016;63:117–25. https://doi.org/10.1002/hep.28283.PubMedCrossRef

63.

Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, et al. The MBOAT7-TMC4 Variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;150:1219e6–1230e6. https://doi.org/10.1053/j.gastro.2016.01.032.CrossRef

64.

Gijón MA, Riekhof WR, Zarini S, Murphy RC, Voelker DR. Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils. J Biol Chem. 2008;283:30235–45. https://doi.org/10.1074/jbc.M806194200.PubMedPubMedCentralCrossRef

65.

Akazawa Y, Nakao K. To die or not to die: death signaling in nonalcoholic fatty liver disease. J Gastroenterol. 2018. https://doi.org/10.1007/s00535-018-1451-5.PubMedCrossRefPubMedCentral

66.

Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology. 2008;48:119–28. https://doi.org/10.1002/hep.22336.PubMedCrossRef

67.

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(367–378):e5. https://doi.org/10.1053/j.gastro.2015.04.005.CrossRef

68.

Marchesini G, Petta S, Dalle Grave R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice. Hepatology. 2016;63:2032–43. https://doi.org/10.1002/hep.28392.PubMedCrossRef

69.

de Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med. 2012;367:1397–406. https://doi.org/10.1056/NEJMoa1203034.PubMedCrossRef

70.

Ebbeling CB, Feldman HA, Chomitz VR, Antonelli TA, Gortmaker SL, Osganian SK, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med. 2012;367:1407–16. https://doi.org/10.1056/NEJMoa1203388.PubMedPubMedCentralCrossRef

71.

Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial. Diabetes. 2012;61:2787–95. https://doi.org/10.2337/db12-0214.PubMedPubMedCentralCrossRef

72.

van der Heijden G-J, Wang ZJ, Chu ZD, Sauer PJJ, Haymond MW, Rodriguez LM, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese. Hispanic Adolescents. Obesity. 2010;18:384–90. https://doi.org/10.1038/oby.2009.274.PubMedCrossRef

73.

DeVore S, Kohli R, Lake K, Nicholas L, Dietrich K, Balistreri WF, et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J Pediatr Gastroenterol Nutr. 2013;57:119–23. https://doi.org/10.1097/MPG.0b013e318290d138.PubMedPubMedCentralCrossRef

74.

Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–88. https://doi.org/10.1053/j.gastro.2015.04.014.PubMedCrossRef

75.

Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Helmrath MA, Brandt ML, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016;374:113–23. https://doi.org/10.1056/NEJMoa1506699.PubMedCrossRef

76.

Manco M, Mosca A, De Peppo F, Caccamo R, Cutrera R, Giordano U, et al. The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis. J Pediatr. 2017;180(31–37):e2. https://doi.org/10.1016/j.jpeds.2016.08.101.CrossRef

77.

Nobili V, Vajro P, Dezsofi A, Fischler B, Hadzic N, Jahnel J, et al. Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr. 2015;60:550–61. https://doi.org/10.1097/MPG.0000000000000715.PubMedCrossRef

78.

Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;21:871–9. https://doi.org/10.1111/j.1365-2036.2005.02420.x.PubMedCrossRef

79.

Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes. 2009;10:5–13. https://doi.org/10.1111/j.1399-5448.2008.00450.x.PubMedCrossRef

80.

Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther. 2008;30:1168–76. https://doi.org/10.1016/j.clinthera.2008.06.012.PubMedCrossRef

81.

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. JAMA. 2011;305:1659. https://doi.org/10.1001/jama.2011.520.PubMedPubMedCentralCrossRef

82.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85. https://doi.org/10.1056/NEJMoa0907929.PubMedPubMedCentralCrossRef

83.

Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734–8.PubMedCrossRef

84.

Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004;38:48–55.PubMedCrossRef

85.

Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1553–61. https://doi.org/10.1111/j.1365-2036.2006.03161.x.PubMedCrossRef

86.

Bjelakovic G, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin a, and vitamin e singly or in different combinations on all-cause mortality: do we have evidence for lack of Harm? PLoS One. 2013;8:e74558. https://doi.org/10.1371/journal.pone.0074558.PubMedPubMedCentralCrossRef

87.

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. In: Bjelakovic G, editor. Cochrane Database Syst. Rev. Chichester: Wiley; 2012. p. CD007176. https://doi.org/10.1002/14651858.cd007176.pub2.CrossRef

88.

Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P, Galli C, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011;96:350–3. https://doi.org/10.1136/adc.2010.192401.PubMedCrossRef

89.

Nobili V, Alisi A, Della Corte C, Risé P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013;23:1066–70. https://doi.org/10.1016/j.numecd.2012.10.010.PubMedCrossRef

90.

Nobili V, Carpino G, Alisi A, De Vito R, Franchitto A, Alpini G, et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One. 2014;9:e88005. https://doi.org/10.1371/journal.pone.0088005.PubMedPubMedCentralCrossRef

91.

Pacifico L, Bonci E, Di Martino M, Versacci P, Andreoli G, Silvestri LM, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2015;25:734–41. https://doi.org/10.1016/j.numecd.2015.04.003.PubMedCrossRef

92.

Janczyk W, Lebensztejn D, Wierzbicka-Rucińska A, Mazur A, Neuhoff-Murawska J, Matusik P, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166(1358–1363):e3. https://doi.org/10.1016/j.jpeds.2015.01.056.CrossRef

93.

Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M, EPE-A Study Group. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147(377–84):e1. https://doi.org/10.1053/j.gastro.2014.04.046.CrossRef

94.

Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2015;49:137–44. https://doi.org/10.1097/MCG.0000000000000099.PubMedPubMedCentralCrossRef

95.

Nobili V, Bedogni G, Donati B, Alisi A, Valenti L. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food. 2013;16:957–60. https://doi.org/10.1089/jmf.2013.0043.PubMedCrossRef

96.

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–131. https://doi.org/10.1038/nature05414.PubMedCrossRef

97.

Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740–3. https://doi.org/10.1097/MPG.0b013e31821f9b85.PubMedCrossRef

98.

Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276–85. https://doi.org/10.1111/apt.12758.PubMedPubMedCentralCrossRef

99.

Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017;64:413–7. https://doi.org/10.1097/MPG.0000000000001422.PubMedCrossRef

100.

Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quiñones L, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci. 2004;106:261–8. https://doi.org/10.1042/CS20030285.PubMedCrossRef

101.

Dohil R, Cabrera BL, Gangoiti JA, Barshop BA, Rioux P. Pharmacokinetics of cysteamine bitartrate following intraduodenal delivery. Fundam Clin Pharmacol. 2014;28:136–43. https://doi.org/10.1111/fcp.12009.PubMedCrossRef

102.

Dohil R, Schmeltzer S, Cabrera BL, Wang T, Durelle J, Duke KB, et al. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33:1036–44. https://doi.org/10.1111/j.1365-2036.2011.04626.x.PubMedCrossRef

103.

Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology. 2016;151(1141–1154):e9. https://doi.org/10.1053/j.gastro.2016.08.027.CrossRef

104.

Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525–31. https://doi.org/10.1053/jhep.2002.36088.PubMedCrossRef

105.

Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. In: Orlando R, editor. Cochrane Database Syst. Rev. Chichester: Wiley; 2007. p. CD005160. https://doi.org/10.1002/14651858.cd005160.pub2.CrossRef

106.

Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr. 2000;136:739–43. https://doi.org/10.1016/S0022-3476(00)26774-7.PubMedCrossRef

107.

Ray K. NAFLD: obeticholic acid for the treatment of fatty liver disease—NASH no more? Nat Rev Gastroenterol Hepatol. 2014;12:1–1. https://doi.org/10.1038/nrgastro.2014.203.PubMedCrossRef

108.

Cariou B, Van Harmelen K, Duran-Sandoval D, Van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039–49. https://doi.org/10.1074/jbc.M510258200.PubMedCrossRef

109.

Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771–84. https://doi.org/10.1194/jlr.M001602.PubMedPubMedCentralCrossRef

110.

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–65. https://doi.org/10.1016/S0140-6736(14)61933-4.PubMedCrossRef

111.

Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, et al. Efficacy and safety of the farnesoid x receptor agonist Obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(574–582):e1. https://doi.org/10.1053/j.gastro.2013.05.042.CrossRef

112.

Derosa G, Sahebkar A, Maffioli P. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. J Cell Physiol. 2018;233:153–61. https://doi.org/10.1002/jcp.25804.PubMedCrossRef

113.

Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720–33. https://doi.org/10.1016/j.jhep.2014.10.039.PubMedCrossRef

114.

Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(1147–1159):e5. https://doi.org/10.1053/j.gastro.2016.01.038.CrossRef

115.

Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting^® 2016. Gilead Website 2016; pp 1:4–6.

116.

Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and nash in morbidly obese patients. PLoS One 2010; 5. https://doi.org/10.1371/journal.pone.0013577.

117.

Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11:1–19. https://doi.org/10.1371/journal.pone.0158156.CrossRef

118.

Friedman S, Sanyal A, Goodman Z, Lefebvre E, Gottwald M, Fischer L, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: cENTAUR Phase 2b study design. Contemp Clin Trials. 2016;47:356–65. https://doi.org/10.1016/j.cct.2016.02.012.PubMedCrossRef

119.

Lefebvre E, Gottwald M, Lasseter K, Chang W, Willett M, Smith PF, et al. Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016;9:139–48. https://doi.org/10.1111/cts.12397.PubMedPubMedCentralCrossRef

120.

Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev. 2005;6(2):169–74. https://doi.org/10.1111/j.1467-789X.2005.00177.x.PubMedCrossRef

121.

Dobrzyn A, Ntambi JM. The role of stearoyl-CoA desaturase in the control of metabolism. Prostaglandins Leukot Essent Fat Acids. 2005;73:35–41. https://doi.org/10.1016/j.plefa.2005.04.011.CrossRef

122.

Leikin-Frenkel A, Goldiner I, Leikin-Gobbi D, Rosenberg R, Bonen H, Litvak A, et al. Treatment of preestablished diet-induced fatty liver by oral fatty acid–bile acid conjugates in rodents. Eur J Gastroenterol Hepatol 2008; 1. https://doi.org/10.1097/meg.0b013e3282fc9743.

123.

Gilat T, Leikin-Frenkel A, Goldiner I, Juhel C, Lafont H, Gobbi D, et al. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology. 2003;38:436–42. https://doi.org/10.1053/jhep.2003.50348.PubMedCrossRef

124.

Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085–91. https://doi.org/10.1016/j.cgh.2014.04.038.PubMedCrossRef

125.

Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64:399–408. https://doi.org/10.1016/j.jhep.2015.08.038.PubMedPubMedCentralCrossRef

126.

Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–90. https://doi.org/10.1016/S0140-6736(15)00803-X.PubMedCrossRef

Titel: Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter
verfasst von: Praveen Kumar Conjeevaram Selvakumar
Mohammad Nasser Kabbany
Naim Alkhouri
Publikationsdatum: 01.08.2018
Verlag: Springer International Publishing
Erschienen in: Pediatric Drugs / Ausgabe 4/2018
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI: https://doi.org/10.1007/s40272-018-0292-2

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter

Abstract

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Update Pädiatrie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens

Dose-Dependent Teratology in Humans: Clinical Implications for Prevention

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder

Helicobacter pylori Infection in Pediatric Patients: Update on Diagnosis and Eradication Strategies

The Use of Ommaya Reservoirs to Deliver Central Nervous System-Directed Chemotherapy in Childhood Acute Lymphoblastic Leukaemia

Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Update Pädiatrie